This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Tuesday's Health Winners & Losers

Also moving higher was Corcept Therapeutics (CORT), which said Monday after market close that it received orphan drug designation from the Food and Drug Administration for Cushing's Syndrome treatment Corlux.

The designation includes seven years of marketing exclusivity from the date of the drug approval, tax credits for the clinical trial costs, marketing filing fee waivers, and assistance in the drug development process from the FDA. It's designed to encourage companies to develop treatments for diseases or conditions affecting fewer than 200,000 patients in the U.S. Corcept rose 19 cents, or 7.6%, to $2.68.

Elsewhere, moving its prospective merger along, Genzyme (GENZ) said it finished its tender offer to acquire the shares of Bioenvision (BIVN). On May 29, the company agreed to acquire Bioenvision in an all-cash transaction of around $345 million, or $5.60 for each outstanding common share and $11.20 for each outstanding preferred share. According to the agreement, Bioenvision will now prepare a proxy statement for its shareholders. The companies expect a merger vote before the end of the year.

Genzyme was down 95 cents, or 1.6%, to $58.86, while Bioenvision edged down 5 cents, or 0.8%, to $5.90 on Tuesday.

Also moving lower on continued merger prospects was eye-care product maker Bausch & Lomb (BOL), whose shares were 1.6% lower at $70.21. The company has filed with regulators to hold a special shareholder meeting to vote on a $65-a-share cash takeover bid by Warburg Pincus. However, Bausch & Lomb said it remains in talks Advanced Medical Optics (EYE), which last week offered $75 a share in cash and stock. Shares of Advanced Medical Optics were also lower, down 1.7% at $34.32.

2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,042.90 -28.32 -0.17%
S&P 500 1,972.29 -5.51 -0.28%
NASDAQ 4,493.39 -12.4620 -0.28%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs